Genetic determinants of amyotrophic lateral sclerosis as therapeutic targets

CNS and Neurological Disorders - Drug Targets

Volumn 9, Issue 6, 2010, Pages 779-790

  Bosco, Daryl A ^a   Landers, John E ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Amyotrophic lateral sclerosis; Genome wide association; Neurodegeneration; Therapy

Indexed keywords

ANGIOGENIC FACTOR; ANGIOGENIN; ARIMOCLOMOL; COPPER ZINC SUPEROXIDE DISMUTASE; DNA BINDING PROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; KINESIN ASSOCIATED PROTEIN 3A; KINESIN ASSOCIATED PROTEIN 3B; MICRORNA; PROTEIN BCL 2; PROTEIN UNC 13 HOMOLOG A; RILUZOLE; SB 509; SMALL INTERFERING RNA; SNARE PROTEIN; TAR DNA BINDING PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CLINICAL FEATURE; CLINICAL TRIAL; DETOXIFICATION; DRUG TARGETING; EXCITOTOXICITY; FAMILIAL AMYOTROPHIC LATERAL SCLEROSIS; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; HUNTINGTON CHOREA; IMMUNOTHERAPY; LIFESPAN; LINKAGE ANALYSIS; MOTONEURON; MOTOR NEURON DISEASE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; ONSET AGE; PARKINSON DISEASE; PASSIVE IMMUNIZATION; PATHOGENESIS; PHENOTYPE; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SPORADIC AMYOTROPHIC LATERAL SCLEROSIS; SYNAPSE VESICLE; VIRAL GENE DELIVERY SYSTEM;

EID: 78649277728     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152710793237494     Document Type: Article

References (158)

1. Tandan, R.; Bradley, W.G. Amyotrophic lateral sclerosis: Part 1. Clinical features, pathology and ethical issues in management. Ann. Neurol., 1985, 18, 271-280.
2. [2] Miller, R.G.; Mitchell, J.D.; Lyon, M.; Moore, D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev., 2007, 1, CD001447.
3. Rosen, D.R.; Siddique, T.; Patterson, D.; Figlewicz, D.A.; Sapp, P.; Hentati, A.; Donaldson, D.; Goto, J.; O'Regan, J.P.; Deng, H.X.; Rahmani, Z.; Krizus, A.; McKenna-Yasek, D.; Cayabyab, A.; Gaston, S.M.; Berger, R.; Tanzi, R.E.; Halperin, J.J.; Herzfeldt, B.; Van den Bergh, R.; Hung, W.Y.; Bird, T.; Deng, G.; Mulder, D.W.; Smyth, C.; Laing, N.G.; Soriano, E.; Pericak-Vance, M.A.; Haines, J.; Rouleau, G.A.; Gusella, J.S.; Horvitz, H.R.; Brown, R.H., Jr. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.Nature, 1993, 362, 59-62.
4. Boillee, S.; Vande Velde, C.; Cleveland, D.W. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron, 2006, 52, 39-59.
5. Rothstein, J.D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol., 2009, 65(Suppl 1), S3-S9.
6. [6] ALSOD: The Amyotrophic Lateral Sclerosis Online Genetic Database. http://alsod.iop.kcl.ac.uk/ [accessed March 11, 2010]
7. Pasinelli, P.; Brown, R.H. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat. Rev. Neurosci., 2006, 7, 710-723.
8. 2-.), superoxide dismutases and related matters. J. Biol. Chem., 1997, 272, 18515-18517.
9. Borchelt, D.R.; Lee, M.K.; Slunt, H.S.; Guarnieri, M.; Xu, Z.S.; Wong, P.C.; Brown, R.H., Jr.; Price, D.L.; Sisodia, S.S.; Cleveland, D.W. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc. Natl. Acad. Sci. USA, 1994, 91, 8292-8296.
10. Gurney, M.E.; Pu, H.; Chiu, A.Y.; Dal Canto, M.C.; Polchow, C.Y.; Alexander, D.D.; Caliendo, J.; Hentati, A.; Kwon, Y.W.; Deng, H.X.; Chen, W.; Zhai, P.; Sufit, R.L.; Siddique, T. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science, 1994, 264, 1772-1775.
11. Bruijn, L.I.; Houseweart, M.K.; Kato, S.; Anderson, K.L.; Anderson, S.D.; Ohama, E.; Reaume, A.G.; Scott, R.W.; Cleveland, D.W. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science, 1998, 281, 1851-1854.
12. Chattopadhyay, M.; Valentine, J.S. Aggregation of copper-zinc superoxide dismutase in familial and sporadic ALS. Antioxid. Redox. Signal., 2009, 11, 1603-1614.
13. Prudencio, M.; Hart, P.J.; Borchelt, D.R.; Andersen, P.M. Variation in aggregation propensities among ALS-associated variants of SOD1: correlation to human disease. Hum. Mol. Genet., 2009, 18, 3217-3226.
14. Pasinelli, P.; Belford, M.E.; Lennon, N.; Bacskai, B.J.; Hyman, B.T.; Trotti, D.; Brown, R.H., Jr. Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron, 2004, 43, 19-30.
15. Urushitani, M.; Sik, A.; Sakurai, T.; Nukina, N.; Takahashi, R.; Julien, J.P. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat. Neurosci., 2006, 9, 108-118.
16. Vande Velde, C.; Miller, T.M.; Cashman, N.R.; Cleveland, D.W. Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria. Proc. Natl. Acad. Sci. USA, 2008, 105, 4022-4027.
17. Magrane, J.; Hervias, I.; Henning, M.S.; Damiano, M.; Kawamata, H.; Manfredi, G. Mutant SOD1 in neuronal mitochondria causes toxicity and mitochondrial dynamics abnormalities. Hum. Mol. Genet., 2009, 18, 4552-4564.
18. Magrane, J.; Manfredi, G. Mitochondrial function, morphology, and axonal transport in amyotrophic lateral sclerosis. Antioxid. Redox. Signal., 2009, 11, 1615-1626.
19. Morfini, G.A.; Burns, M.; Binder, L.I.; Kanaan, N.M.; LaPointe, N.; Bosco, D.A.; Brown, R.H., Jr.; Brown, H.; Tiwari, A.; Hayward, L.; Edgar, J.; Nave, K.A.; Garberrn, J.; Atagi, Y.; Song, Y.; Pigino, G.; Brady, S.T. Axonal transport defects in neurodegenerative diseases. J. Neurosci., 2009, 29, 12776-12786.
20. Tateno, M.; Kato, S.; Sakurai, T.; Nukina, N.; Takahashi, R.; Araki, T. Mutant SOD1 impairs axonal transport of choline acetyltransferase and acetylcholine release by sequestering KAP3. Hum. Mol. Genet., 2009, 18, 942-955.
21. Julien, J.P.; Kriz, J. Transgenic mouse models of amyotrophic lateral sclerosis. Biochim. Biophys. Acta, 2006, 1762, 1013-1024.
22. Nagai, M.; Aoki, M.; Miyoshi, I.; Kato, M.; Pasinelli, P.; Kasai, N.; Brown, R.H., Jr.; Itoyama, Y. Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J. Neurosci., 2001, 21, 9246-9254.
23. Broom, W.J.; Auwarter, K.E.; Ni, J.; Russel, D.E.; Yeh, L.A.; Maxwell, M.M.; Glicksman, M.; Kazantsev, A.G.; Brown, R.H., Jr. Two approaches to drug discovery in SOD1-mediated ALS. J. Biomol. Screen., 2006, 11, 729-735.
24. Maxwell, M.M. RNAi applications in therapy development for neurodegenerative disease. Curr. Pharm. Des., 2009, 15, 3977-3991.
25. Tomari, Y.; Zamore, P.D. Perspective: machines for RNAi. Genes Dev., 2005, 19, 517-529.
26. Crooke, S.T. Molecular mechanisms of action of antisense drugs. Biochim. Biophys. Acta, 1999, 1489, 31-44.
27. Ralph, G.S.; Radcliffe, P.A.; Day, D.M.; Carthy, J.M.; Leroux, M.A.; Lee, D.C.; Wong, L.F.; Bilsland, L.G.; Greensmith, L.; Kingsman, S.M.; Mitrophanous, K.A.; Mazarakis, N.D.; Azzouz, M. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med., 2005, 11, 429-433.
28. Raoul, C.; Abbas-Terki, T.; Bensadoun, J.C.; Guillot, S.; Haase, G.; Szulc, J.; Henderson, C.E.; Aebischer, P. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med., 2005, 11, 423-428.
29. Wang, H.; Ghosh, A.; Baigude, H.; Yang, C.S.; Qiu, L.; Xia, X.; Zhou, H.; Rana, T.M.; Xu, Z. Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression. J. Biol. Chem., 2008, 283, 15845-15852.
30. Turner, M.R.; Kiernan, M.C.; Leigh, P.N.; Talbot, K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol., 2009, 8, 94-109.
31. Xia, X.; Zhou, H.; Huang, Y.; Xu, Z. Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiol. Dis., 2006, 23, 578-586.
32. Reaume, A.; Elliott, J.; Hoffman, E.; Kowall, N.; Ferrante, R.; Siwek, D.; Wilcox, H.; Flood, D.; Beal, M.; Brown, R.; Scott, R.; Snyder, W. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet., 1996, 13, 43-47.
33. Barber, S.C.; Mead, R.J.; Shaw, P.J. Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim. Biophys. Acta, 2006, 1762, 1051-1067.
34. Urushitani, M.; Ezzi, S.A.; Julien, J.P. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA, 2007, 104, 2495-2500.
35. Wong, P.C.; Pardo, C.A.; Borchelt, D.R.; Lee, M.K.; Copeland, N.G.; Jenkins, N.A.; Sisodia, S.S.; Cleveland, D.W.; Price, D.L. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron, 1995, 14, 1105-1116.
36. Jonsson, P.A.; Graffmo, K.S.; Andersen, P.M.; Brannstrom, T.; Lindberg, M.; Oliveberg, M.; Marklund, S.L. Disulphide-reduced superoxide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models. Brain, 2006, 129, 451-464.
37. Sawkar, A.R.; Schmitz, M.; Zimmer, K.P.; Reczek, D.; Edmunds, T.; Balch, W.E.; Kelly, J.W. Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants. ACS Chem. Biol., 2006, 1, 235-251.
38. Adamski-Werner, S.L.; Palaninathan, S.K.; Sacchettini, J.C.; Kelly, J.W. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J. Med. Chem., 2004, 47, 355-374.
39. Ray, S.S.; Nowak, R.J.; Brown, R.H., Jr.; Lansbury, P.T., Jr. Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Proc. Natl. Acad. Sci. USA, 2005, 102, 3639-3644.
40. Ray, S.S.; Nowak, R.J.; Strokovich, K.; Brown, R.H., Jr.; Walz, T.; Lansbury, P.T., Jr. An intersubunit disulfide bond prevents in vitro aggregation of a superoxide dismutase-1 mutant linked to familial amytrophic lateral sclerosis. Biochemistry, 2004, 43, 4899-4905.
41. Rakhit, R.; Crow, J.P.; Lepock, J.R.; Kondejewski, L.H.; Cashman, N.R.; Chakrabartty, A. Monomeric Cu, Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic lateral sclerosis. J. Biol. Chem., 2004, 279, 15499-15504.
42. Rakhit, R.; Robertson, J.; Velde, C.V.; Horne, P.; Ruth, D.M.; Griffin, J.; Cleveland, D.W.; Cashman, N.R.; Chakrabartty, A. An immunological epitope selective for pathological monomer-misfolded SOD1 in ALS. Nat. Med., 2007, 13, 754-759.
43. Molnar, K.S.; Karabacak, N.M.; Johnson, J.L.; Wang, Q.; Tiwari, A.; Hayward, L.J.; Coales, S.J.; Hamuro, Y.; Agar, J.N. A common property of amyotrophic lateral sclerosis-associated variants: Destabilization of the Cu/Zn superoxide dismutase electrostatic loop. J. Biol. Chem., 2009, 284, 30965-30973.
44. Bruening, W.; Roy, J.; Giasson, B.; Figlewicz, D.A.; Mushynski, W.E.; Durham, H.D. Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis. J. Neurochem., 1999, 72, 693-699.
45. Lanka, V.; Wieland, S.; Barber, J.; Cudkowicz, M. Arimoclomol: a potential therapy under development for ALS. Expert Opin. Investig. Drugs, 2009, 18, 1907-1918.
46. Kalmar, B.; Novoselov, S.; Gray, A.; Cheetham, M.E.; Margulis, B.; Greensmith, L. Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. J. Neurochem., 2008, 107, 339-350.
47. Kieran, D.; Kalmar, B.; Dick, J.R.; Riddoch-Contreras, J.; Burnstock, G.; Greensmith, L. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat. Med., 2004, 10, 402-405.
48. Neumann, M.; Sampathu, D.M.; Kwong, L.K.; Truax, A.C.; Micsenyi, M.C.; Chou, T.T.; Bruce, J.; Schuck, T.; Grossman, M.; Clark, C.M.; McCluskey, L.F.; Miller, B.L.; Masliah, E.; Mackenzie, I.R.; Feldman, H.; Feiden, W.; Kretzschmar, H.A.; Trojanowski, J.Q.; Lee, V.M. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 2006, 314, 130-133.
49. Bossy-Wetzel, E.; Schwarzenbacher, R.; Lipton, S.A. Molecular pathways to neurodegeneration. Nat. Med., 2004, 10(Suppl), S2-S9.
50. Ezzi, S.A.; Urushitani, M.; Julien, J.P. Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J. Neurochem., 2007, 102, 170-178.
51. Rakhit, R.; Cunningham, P.; Furtos-Matei, A.; Dahan, S.; Qi, X.F.; Crow, J.P.; Cashman, N.R.; Kondejewski, L.H.; Chakrabartty, A. Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. J. Biol. Chem., 2002, 277, 47551-47556.
52. Beckman, J.S.; Estevez, A.G.; Crow, J.P.; Barbeito, L. Superoxide dismutase and the death of motoneurons in ALS. Trends Neurosci., 2001, 24, S15-S20.
53. Estevez, A.G.; Crow, J.P.; Sampson, J.B.; Reiter, C.; Zhuang, Y.; Richardson, G.J.; Tarpey, M.M.; Barbeito, L.; Beckman, J.S. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science, 1999, 286, 2498-2500.
54. Gruzman, A.; Wood, W.L.; Alpert, E.; Prasad, M.D.; Miller, R.G.; Rothstein, J.D.; Bowser, R.; Hamilton, R.; Wood, T.D.; Cleveland, D.W.; Lingappa, V.R.; Liu, J. Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA, 2007, 104, 12524-12529.
55. Liu, H.N.; Sanelli, T.; Horne, P.; Pioro, E.P.; Strong, M.J.; Rogaeva, E.; Bilbao, J.; Zinman, L.; Robertson, J. Lack of evidence of monomer/misfolded superoxide dismutase-1 in sporadic amyotrophic lateral sclerosis. Ann. Neurol., 2009, 66, 75-80.
56. Andersson, M.K.; Stahlberg, A.; Arvidsson, Y.; Olofsson, A.; Semb, H.; Stenman, G.; Nilsson, O.; Aman, P. The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response. BMC Cell Biol., 2008, 9, 37.
57. Ayala, Y.M.; Zago, P.; D'Ambrogio, A.; Xu, Y.F.; Petrucelli, L.; Buratti, E.; Baralle, F.E. Structural determinants of the cellular localization and shuttling of TDP-43. J. Cell Sci., 2008, 121, 3778-3785.
58. Lagier-Tourenne, C.; Cleveland, D.W. Rethinking ALS: the FUS about TDP-43. Cell, 2009, 136, 1001-1004.
59. Buratti, E.; Baralle, F.E. Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Front. Biosci., 2008, 13, 867-878.
60. Wang, X.; Arai, S.; Song, X.; Reichart, D.; Du, K.; Pascual, G.; Tempst, P.; Rosenfeld, M.G.; Glass, C.K.; Kurokawa, R. Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature, 2008, 454, 126-130.
61. Buratti, E.; Dork, T.; Zuccato, E.; Pagani, F.; Romano, M.; Baralle, F.E. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J., 2001, 20, 1774-1784.
62. Yang, L.; Embree, L.J.; Hickstein, D.D. TLS-ERG leukemia fusion protein inhibits RNA splicing mediated by serine-arginine proteins. Mol. Cell Biol., 2000, 20, 3345-3354.
63. Zinszner, H.; Sok, J.; Immanuel, D.; Yin, Y.; Ron, D. TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. J. Cell Sci., 1997, 110(Pt 15), 1741-1750.
64. Sreedharan, J.; Blair, I.P.; Tripathi, V.B.; Hu, X.; Vance, C.; Rogelj, B.; Ackerley, S.; Durnall, J.C.; Williams, K.L.; Buratti, E.; Baralle, F.; de Belleroche, J.; Mitchell, J.D.; Leigh, P.N.; Al-Chalabi, A.; Miller, C.C.; Nicholson, G.; Shaw, C.E. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science, 2008, 319, 1668-1672.
65. Kabashi, E.; Valdmanis, P.N.; Dion, P.; Spiegelman, D.; McConkey, B.J.; Vande Velde, C.; Bouchard, J.P.; Lacomblez, L.; Pochigaeva, K.; Salachas, F.; Pradat, P.F.; Camu, W.; Meininger, V.; Dupre, N.; Rouleau, G.A. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet., 2008, 40, 572-574.
66. Van Deerlin, V.M.; Leverenz, J.B.; Bekris, L.M.; Bird, T.D.; Yuan, W.; Elman, L.B.; Clay, D.; Wood, E.M.; Chen-Plotkin, A.S.; Martinez-Lage, M.; Steinbart, E.; McCluskey, L.; Grossman, M.; Neumann, M.; Wu, I.L.; Yang, W.S.; Kalb, R.; Galasko, D.R.; Montine, T.J.; Trojanowski, J.Q.; Lee, V.M.; Schellenberg, G.D.; Yu, C.E. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol., 2008, 7, 409-416.
67. Benajiba, L.; Le Ber, I.; Camuzat, A.; Lacoste, M.; Thomas-Anterion, C.; Couratier, P.; Legallic, S.; Salachas, F.; Hannequin, D.; Decousus, M.; Lacomblez, L.; Guedj, E.; Golfier, V.; Camu, W.; Dubois, B.; Campion, D.; Meininger, V.; Brice, A. TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann. Neurol., 2009, 65, 470-473.
68. Corrado, L.; Ratti, A.; Gellera, C.; Buratti, E.; Castellotti, B.; Carlomagno, Y.; Ticozzi, N.; Mazzini, L.; Testa, L.; Taroni, F.; Baralle, F.E.; Silani, V.; D'Alfonso, S. High frequency of TARDBP gene mutations in Italian patients with amyotrophic lateral sclerosis. Hum. Mutat., 2009, 30, 688-694.
69. Daoud, H.; Valdmanis, P.N.; Kabashi, E.; Dion, P.; Dupre, N.; Camu, W.; Meininger, V.; Rouleau, G.A. Contribution of TARDBP mutations to sporadic amyotrophic lateral sclerosis. J. Med. Genet., 2009, 46, 112-114.
70. Ticozzi, N.; Silani, V.; LeClerc, A.L.; Keagle, P.; Gellera, C.; Ratti, A.; Taroni, F.; Kwiatkowski, T.J., Jr.; McKenna-Yasek, D.M.; Sapp, P.C.; Brown, R.H., Jr.; Landers, J.E. Analysis of FUS gene mutation in familial amyotrophic lateral sclerosis within an Italian cohort. Neurology, 2009, 73, 1180-1185.
71. Kwiatkowski, T.J., Jr.; Bosco, D.A.; Leclerc, A.L.; Tamrazian, E.; Vanderburg, C.R.; Russ, C.; Davis, A.; Gilchrist, J.; Kasarskis, E.J.; Munsat, T.; Valdmanis, P.; Rouleau, G.A.; Hosler, B.A.; Cortelli, P.; de Jong, P.J.; Yoshinaga, Y.; Haines, J.L.; Pericak-Vance, M.A.; Yan, J.; Ticozzi, N.; Siddique, T.; McKenna-Yasek, D.; Sapp, P.C.; Horvitz, H.R.; Landers, J.E.; Brown, R.H., Jr. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science, 2009, 323, 1205-1208.
72. Vance, C.; Rogelj, B.; Hortobagyi, T.; De Vos, K.J.; Nishimura, A.L.; Sreedharan, J.; Hu, X.; Smith, B.; Ruddy, D.; Wright, P.; Ganesalingam, J.; Williams, K.L.; Tripathi, V.; Al-Saraj, S.; Al-Chalabi, A.; Leigh, P.N.; Blair, I.P.; Nicholson, G.; de Belleroche, J.; Gallo, J.M.; Miller, C.C.; Shaw, C.E. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science, 2009, 323, 1208-1211.
73. Corrado, L.; Del Bo, R.; Castellotti, B.; Ratti, A.; Cereda, C.; Penco, S.; Soraru, G.; Carlomagno, Y.; Ghezzi, S.; Pensato, V.; Colombrita, C.; Gagliardi, S.; Cozzi L.; Orsetti, V.; Mancuso, M.; Siciliano, G.; Mazzini, L.; Comi, G.P.; Gellera, C.; Ceroni, M.; D'Alfonso, S.; Silani, V. Mutations of FUS gene in sporadic amyotrophic lateral sclerosis. J. Med. Genet., 2009, 47, 190-194.
74. Damme, P.V.; Goris, A.; Race, V.; Hersmus, N.; Dubois, B.; Bosch, L.V.; Matthijs, G.; Robberecht, W. The occurrence of mutations in FUS in a Belgian cohort of patients with familial ALS. Eur. J. Neurol., 2010, 17, 754-756.
75. Mackenzie, I.R.; Bigio, E.H.; Ince, P.G.; Geser, F.; Neumann, M.; Cairns, N.J.; Kwong, L.K.; Forman, M.S.; Ravits, J.; Stewart, H.; Eisen, A.; McClusky, L.; Kretzschmar, H.A.; Monoranu, C.M.; Highley, J.R.; Kirby, J.; Siddique, T.; Shaw, P.J.; Lee, V.M.; Trojanowski, J.Q. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann. Neurol., 2007, 61, 427-434.
76. Tan, C.F.; Eguchi, H.; Tagawa, A.; Onodera, O.; Iwasaki, T.; Tsujino, A.; Nishizawa, M.; Kakita, A.; Takahashi, H. TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol., 2007, 113, 535-542.
77. Pesiridis, G.S.; Lee, V.M.; Trojanowski, J.Q. Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum. Mol. Genet., 2009, 18, R156-R162.
78. Wegorzewska, I.; Bell, S.; Cairns, N.J.; Miller, T.M.; Baloh, R.H. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA, 2009, 106, 18809-18814.
79. Barmada, S.J.; Skibinski, G.; Korb, E.; Rao, E.J.; Wu, J.Y.; Finkbeiner, S. Cytoplasmic, mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J. Neurosci., 2010, 30, 639-649.
80. Zakaryan, R.P.; Gehring, H. Identification and characterization of the nuclear localization/retention signal in the EWS proto-oncoprotein. J. Mol. Biol., 2006, 363, 27-38.
81. Neumann, M.; Rademakers, R.; Roeber, S.; Baker, M.; Kretzschmar, H.A.; Mackenzie, I.R. Frontotemporal lobar degeneration with FUS pathology. Brain, 2009, 132, 2922-2931.
82. Munoz, D.G.; Neumann, M.; Kusaka, H.; Yokota, O.; Ishihara, K.; Terada, S.; Kuroda, S.; Mackenzie, I.R. FUS pathology in basophilic inclusion body disease. Acta Neuropathol., 2009, 118, 617-627.
83. Neumann, M.; Roeber, S.; Kretzschmar, H.A.; Rademakers, R.; Baker, M.; Mackenzie, I.R. Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol., 2009, 118, 605-616.
84. Kishimoto, K.; Liu, S.; Tsuji, T.; Olson, K.A.; Hu, G.F. Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene, 2005, 24, 445-456.
85. Oosthuyse, B.; Moons, L.; Storkebaum, E.; Beck, H.; Nuyens, D.; Brusselmans, K.; Van Dorpe, J.; Hellings, P.; Gorselink M.; Heymans, S.; Theilmeier, G.; Dewerchin, M.; Laudenbach, V.; Vermylen, P.; Raat, H.; Acker, T.; Vleminckx, V.; Van Den Bosch, L.; Cashman, N.; Fujisawa, H.; Drost, M.R.; Sciot, R.; Bruyninckx, F.; Hicklin, D.J.; Ince, C.; Gressens, P.; Lupu, F.; Plate, K.H.; Robberecht, W.; Herbert, J.M.; Collen, D.; Carmeliet, P. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet., 2001, 28, 131-138.
86. Greenway, M.J.; Andersen, P.M.; Russ, C.; Ennis, S.; Cashman, S.; Donaghy, C.; Patterson, V.; Swingler, R.; Kieran, D.; Prehn, J.; Morrison, K.E.; Green, A.; Acharya, K.R.; Brown, R.H., Jr.; Hardiman, O. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat. Genet., 2006, 38, 411-413.
87. Wu, D.; Yu, W.; Kishikawa, H.; Folkerth, R.D.; Iafrate, A.J.; Shen, Y.; Xin, W.; Sims, K.; Hu, G.F. Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis. Ann. Neurol., 2007, 62, 609-617.
88. Gellera, C.; Colombrita, C.; Ticozzi, N.; Castellotti, B.; Bragato, C.; Ratti, A.; Taroni, F.; Silani, V. Identification of new ANG gene mutations in a large cohort of Italian patients with amyotrophic lateral sclerosis. Neurogenetics, 2008, 9, 33-40.
89. van Es, M.A.; Diekstra, F.P.; Veldink, J.H.; Baas, F.; Bourque, P.R.; Schelhaas, H.J.; Strengman, E.; Hennekam, E.A.; Lindhout, D.; Ophoff, R.A.; van den Berg, L.H. A case of ALS-FTD in a large FALS pedigree with a K17I ANG mutation. Neurology, 2009, 72, 287-288.
90. Paubel, A.; Violette, J.; Amy, M.; Praline, J.; Meininger, V.; Camu, W.; Corcia, P.; Andres, C.R.; Vourc'h, P. Mutations of the ANG gene in French patients with sporadic amyotrophic lateral sclerosis. Arch. Neurol., 2008, 65, 1333-1336.
91. Conforti, F.L.; Sprovieri, T.; Mazzei, R.; Ungaro, C.; La Bella, V.; Tessitore, A.; Patitucci, A.; Magariello, A.; Gabriele, A.L.; Tedeschi, G.; Simone, I.L.; Majorana, G.; Valentino, P.; Condino, F.; Bono, F.; Monsurro, M.R.; Muglia, M.; Quattrone, A. A novel Angiogenin gene mutation in a sporadic patient with amyotrophic lateral sclerosis from southern Italy. Neuromuscul. Disord., 2008, 18, 68-70.
92. Crabtree, B.; Thiyagarajan, N.; Prior, S.H.; Wilson, P.; Iyer, S.; Ferns, T.; Shapiro, R.; Brew, K.; Subramanian, V.; Acharya, K.R. Characterization of human angiogenin variants implicated in amyotrophic lateral sclerosis. Biochemistry, 2007, 46, 11810-11818.
93. Subramanian, V.; Crabtree, B.; Acharya, K.R. Human angiogenin is a neuroprotective factor and amyotrophic lateral sclerosis associated angiogenin variants affect neurite extension/pathfinding and survival of motor neurons. Hum. Mol. Genet., 2008, 17, 130-149.
94. Moenner, M.; Gusse, M.; Hatzi, E.; Badet, J. The widespread expression of angiogenin in different human cells suggests a biological function not only related to angiogenesis. Eur. J. Biochem., 1994, 226, 483-490.
95. Kulka, M.; Fukuishi, N.; Metcalfe, D.D. Human mast cells synthesize and release angiogenin, a member of the ribonuclease A (RNase A) superfamily. J. Leukoc. Biol., 2009, 85, 1217-1226.
96. Huang, L.; Huang, Y.; Guo, H. Dominant expression of angiogenin in NeuN positive cells in the focal ischemic rat brain. J. Neurol. Sci., 2009, 285, 220-223.
97. Moroianu, J.; Riordan, J.F. Identification of the nucleolar targeting signal of human angiogenin. Biochem. Biophys. Res. Commun., 1994, 203, 1765-1772.
98. Moroianu, J.; Riordan, J.F. Nuclear translocation of angiogenin in proliferating endothelial cells is essential to its angiogenic activity. Proc. Natl. Acad. Sci. USA, 1994, 91, 1677-1681.
99. Shapiro, R. Structural features that determine the enzymatic potency and specificity of human angiogenin: threonine-80 and residues 58-70 and 116-123. Biochemistry, 1998, 37, 6847-6856.
100. Saxena, S.K.; Rybak, S.M.; Davey, R.T., Jr.; Youle, R.J.; Ackerman, E.J. Angiogenin is a cytotoxic, tRNA-specific ribonuclease in the RNase A superfamily. J. Biol. Chem., 1992, 267, 21982-21986.
101. Yamasaki, S.; Ivanov, P.; Hu, G.F.; Anderson P. Angiogenin cleaves tRNA and promotes stress-induced translational repression. J. Cell Biol., 2009, 185, 35-42.
102. Xu, Z.P.; Tsuji, T.; Riordan, J.F.; Hu, G.F. The nuclear function of angiogenin in endothelial cells is related to rRNA production. Biochem. Biophys. Res. Commun., 2002, 294, 287-292.
103. Xu, Z.P.; Tsuji, T.; Riordan, J.F.; Hu, G.F. Identification and characterization of an angiogenin-binding DNA sequence that stimulates luciferase reporter gene expression. Biochemistry, 2003, 42, 121-128.
104. Kieran, D.; Sebastia, J.; Greenway, M.J.; King, M.A.; Connaughton, D.; Concannon, C.G.; Fenner, B.; Hardiman, O.; Prehn, J.H. Control of motoneuron survival by angiogenin. J. Neurosci., 2008, 28, 14056-14061.
105. Sebastia, J.; Kieran, D.; Breen, B.; King, M.A.; Netteland, D.F.; Joyce, D.; Fitzpatrick, S.F.; Taylor, C.T.; Prehn, J.H. Angiogenin protects motoneurons against hypoxic injury. Cell Death Differ., 2009, 16, 1238-1247.
106. Subramanian, V.; Feng, Y. A new role for angiogenin in neurite growth and pathfinding: implications for amyotrophic lateral sclerosis. Hum. Mol. Genet., 2007, 16, 1445-1453.
107. Moreau, C.; Gosset, P.; Brunaud-Danel, V.; Lassalle, P.; Degonne, B.; Destee, A.; Defebvre, L.; Devos, D. CSF profiles of angiogenic and inflammatory factors depend on the respiratory status of ALS patients. Amyotroph. Later. Scler., 2009, 10, 175-181.
108. Cronin, S.; Greenway, M.J.; Ennis, S.; Kieran, D.; Green, A.; Prehn, J.H.; Hardiman, O. Elevated serum angiogenin levels in ALS. Neurology, 2006, 67, 1833-1836.
109. Azzouz, M.; Ralph, G.S.; Storkebaum, E.; Walmsley, L.E.; Mitrophanous, K.A.; Kingsman, S.M.; Carmeliet, P.; Mazarakis, N.D. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature, 2004, 429, 413-417.
110. Ott, J. Analysis of Human Genetics; Baltimore: University Press: Johns Hopkins, 1991.
111. Bodmer, W.; Bonilla, C. Common and rare variants in multifactorial susceptibility to common diseases. Nat. Genet., 2008, 40, 695-701.
112. Simon-Sanchez, J.; Singleton, A. Genome-wide association studies in neurological disorders. Lancet Neurol., 2008, 7, 1067-1072.
113. Manolio, T.A.; Collins, F.S. The HapMap and genome-wide association studies in diagnosis and therapy. Annu. Rev. Med., 2009, 60, 443-456.
114. Orr, N.; Chanock, S. Common genetic variation and human disease. Adv. Genet., 2008, 62, 1-32.
115. Schymick, J.C.; Scholz, S.W.; Fung, H.C.; Britton, A.; Arepalli, S.; Gibbs, J.R.; Lombardo, F.; Matarin, M.; Kasperaviciute, D.; Hernandez, D.G.; Crews, C.; Bruijn, L.; Rothstein, J.; Mora, G.; Restagno, G.; Chio, A.; Singleton, A.; Hardy, J.; Traynor, B.J. Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol., 2007, 6, 322-328.
116. Dunckley, T.; Huentelman, M.J.; Craig, D.W.; Pearson, J.V.; Szelinger, S.; Joshipura, K.; Halperin, R.F.; Stamper, C.; Jensen, K.R.; Letizia, D.; Hesterlee, S.E.; Pestronk, A.; Levine, T.; Bertorini, T.; Graves, M.C.; Mozaffar, T.; Jackson, C.E.; Bosch, P.; McVey, A.; Dick, A.; Barohn, R.; Lomen-Hoerth, C.; Rosenfeld, J.; O'Connor, D.T.; Zhang, K.; Crook, R.; Ryberg, H.; Hutton, M.; Katz, J.; Simpson, E.P.; Mitsumoto, H.; Bowser, R.; Miller, R.G.; Appel, S.H.; Stephan, D.A. Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N. Engl. J. Med., 2007, 357, 775-788.
117. [117] Fernandez-Santiago, R.; Sharma, M.; Berg, D.; Illig, T.; Anneser, J.; Meyer, T.; Ludolph, A.; Gasser, T. No evidence of association of FLJ10986 and ITPR2 with ALS in a large German cohort. Neurobiol. Aging, 2009, [Epub ahead of print].
118. Meissner, M.; Lopato, S.; Gotzmann, J.; Sauermann, G.; Barta, A. Proto-oncoprotein TLS/FUS is associated to the nuclear matrix and complexed with splicing factors PTB, SRm160, and SR proteins. Exp. Cell. Res., 2003, 283, 184-195.
119. Van Es, M.A.; Van Vught, P.W.; Veldink, J.H.; Andersen, P.M.; Birve, A.; Lemmens, R.; Cronin, S.; Van Der Kooi, A.J.; Visser, M.D.; Schelhaas, H.J.; Hardiman, O.; Ragoussis, I.; Lambrechts, D.; Robberecht, W.; Wokke, J.H.; Ophoff, R.A.; Van Den Berg, L.H. Analysis of FGGY as a risk factor for sporadic amyotrophic lateral sclerosis. Amyotroph. Later. Scler., 2009, 10(5-6), 441-447.
120. van Es, M.A.; Van Vught, P.W.; Blauw, H.M.; Franke, L.; Saris, C.G.; Andersen, P.M.; Van Den Bosch, L.; de Jong, S.W.; van 't Slot, R.; Birve, A.; Lemmens, R.; de Jong, V.; Baas, F.; Schelhaas, H.J.; Sleegers, K.; Van Broeckhoven, C.; Wokke, J.H.; Wijmenga, C.; Robberecht, W.; Veldink, J.H.; Ophoff, R.A.; van den Berg, L.H. ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurol., 2007, 6, 869-877.
121. Okado-Matsumoto, A.; Fridovich, I. Assay of superoxide dismutase: cautions relevant to the use of cytochrome c, a sulfonated tetrazolium, and cyanide. Anal. Biochem., 2001, 298, 337-342.
122. van Es, M.A.; van Vught, P.W.; Blauw, H.M.; Franke, L.; Saris, C.G.; Van den Bosch, L.; de Jong, S.W.; de Jong, V.; Baas, F.; van't Slot, R.; Lemmens, R.; Schelhaas, H.J.; Birve, A.; Sleegers, K.; Van Broeckhoven, C.; Schymick, J.C.; Traynor, B.J.; Wokke, J.H.; Wijmenga, C.; Robberecht, W.; Andersen, P.M.; Veldink, J.H.; Ophoff, R.A.; van den Berg, L.H. Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis. Nat. Genet., 2008, 40, 29-31.
123. Cronin, S.; Berger, S.; Ding, J.; Schymick, J.C.; Washecka, N.; Hernandez, D.G.; Greenway, M.J.; Bradley, D.G.; Traynor, B.J.; Hardiman, O. A genome-wide association study of sporadic ALS in a homogenous Irish population. Hum. Mol. Genet., 2008, 17, 768-774.
124. Cronin, S.; Tomik, B.; Bradley, D.G.; Slowik, A.; Hardiman, O. Screening for replication of genome-wide SNP associations in sporadic ALS. Eur. J. Hum. Genet., 2009, 17, 213-218.
125. Landers, J.E.; Melki, J.; Meininger, V.; Glass, J.D.; van den Berg, L.H.; van Es, M.A.; Sapp, P.C.; van Vught, P.W.J.; McKenna-Yasek, D.M.; Blauw, H.M.; Cho, T.-J.; Polak, M.; Shi, L.; Wills, A.-M.; Broom, W.J.; Ticozzi, N.; Silani, V.; Ozoguz, A.; Rodriguez-Leyva, I.; Veldink, J.H.; Ivinson, A.J.; Saris, C.G.J.; Hosler, B.A.; Barnes-Nessa, A.; Couture, N.; Wokke, J.H.J.; Kwiatkowski, T.J.; Ophoff, R.A.; Cronin, S.; Hardiman, O.; Diekstra, F.P.; Leigh, P.N.; Shaw, C.E.; Simpson, C.L.; Hansen, V.K.; Powell, J.F.; Corcia, P.; Salachas, F.; Heath, S.; Galan, P.; Georges, F.; Horvitz, H.R.; Lathrop, M.; Purcell, S.; Al-Chalabi, A.; Brown, R.H. Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA, 2009, 106, 9004-9009.
126. Takeda, S.; Yamazaki, H.; Seog, D.H.; Kanai, Y.; Terada, S.; Hirokawa, N. Kinesin superfamily protein 3 (KIF3) motor transports fodrin-associating vesicles important for neurite building. J. Cell Biol., 2000, 148, 1255-1265.
127. Teng, J.; Rai, T.; Tanaka, Y.; Takei, Y.; Nakata, T.; Hirasawa, M.; Kulkarni, A.B.; Hirokawa, N. The KIF3 motor transports N- cadherin and organizes the developing neuroepithelium. Nat. Cell Biol., 2005, 7, 474-482.
128. Brown, C.L.; Maier, K.C.; Stauber, T.; Ginkel, L.M.; Wordeman, L.; Vernos, I.; Schroer, T.A. Kinesin-2 is a motor for late endosomes and lysosomes. Traffic, 2005, 6, 1114-1124.
129. Stauber, T.; Simpson, J.C.; Pepperkok, R.; Vernos, I. A role for kinesin-2 in COPI-dependent recycling between the ER and the Golgi complex. Curr. Biol., 2006, 16, 2245-2251.
130. Yamazaki, H.; Nakata, T.; Okada, Y.; Hirokawa, N. Cloning and characterization of KAP3: a novel kinesin superfamily-associated protein of KIF3A/3B. Proc. Natl. Acad. Sci. USA, 1996, 93, 8443-8448.
131. Yamazaki, H.; Nakata, T.; Okada, Y.; Hirokawa, N. KIF3A/B: a heterodimeric kinesin superfamily protein that works as a microtubule plus end-directed motor for membrane organelle transport. J. Cell Biol., 1995, 130, 1387-1399.
132. Dupuis, L.; de Tapia, M.; Rene, F.; Lutz-Bucher, B.; Gordon, J.W.; Mercken, L.; Pradier, L.; Loeffler, J.P. Differential screening of mutated SOD1 transgenic mice reveals early up-regulation of a fast axonal transport component in spinal cord motor neurons. Neurobiol. Dis., 2000, 7, 274-285.
133. Law, W.J.; Cann, K.L.; Hicks, G.G. TLS, EWS and TAF15: a model for transcriptional integration of gene expression. Brief Funct. Genomic Proteomics, 2006, 5, 8-14.
134. van Es, M.A.; Veldink, J.H.; Saris, C.G.; Blauw, H.M.; van Vught, P.W.; Birve, A.; Lemmens, R.; Schelhaas, H.J.; Groen, E.J.; Huisman, M.H.; van der Kooi, A.J.; de Visser, M.; Dahlberg, C.; Estrada, K.; Rivadeneira, F.; Hofman, A.; Zwarts, M.J.; van Doormaal, P.T.; Rujescu, D.; Strengman, E.; Giegling, I.; Muglia, P.; Tomik, B.; Slowik, A.; Uitterlinden, A.G.; Hendrich, C.; Waibel, S.; Meyer, T.; Ludolph, A.C.; Glass, J.D.; Purcell, S.; Cichon, S.; Nothen, M.M.; Wichmann, H.E.; Schreiber, S.; Vermeulen, S.H.; Kiemeney, L.A.; Wokke, J.H.; Cronin, S.; McLaughlin, R.L.; Hardiman, O.; Fumoto, K.; Pasterkamp, R.J.; Meininger, V.; Melki, J.; Leigh, P.N.; Shaw, C.E.; Landers, J.E.; Al-Chalabi, A.; Brown, R.H., Jr.; Robberecht, W.; Andersen, P.M.; Ophoff, R.A.; van den Berg, L.H. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat. Genet., 2009, 41, 1083-1087.
135. Morita, M.; Al-Chalabi, A.; Andersen, P.M.; Hosler, B.; Sapp, P.; Englund, E.; Mitchell, J.E.; Habgood, J.J.; de Belleroche, J.; Xi, J.; Jongjaroenprasert, W.; Horvitz, H.R.; Gunnarsson, L.G.; Brown, R.H., Jr. A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology, 2006, 66, 839-844.
136. Vance, C.; Al-Chalabi, A.; Ruddy, D.; Smith, B.N.; Hu, X.; Sreedharan, J.; Siddique, T.; Schelhaas, H.J.; Kusters, B.; Troost, D.; Baas, F.; de Jong, V.; Shaw, C.E. Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Brain, 2006, 129, 868-876.
137. Sutton, R.B.; Fasshauer, D.; Jahn, R.; Brunger, A.T. Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution. Nature, 1998, 395, 347-353.
138. Sudhof, T.C. The synaptic vesicle cycle. Annu. Rev. Neurosci., 2004, 27, 509-547.
139. Jahn, R.; Scheller, R.H. SNAREs--engines for membrane fusion. Nat. Rev. Mol. Cell Biol., 2006, 7, 631-643.
140. Varoqueaux, F.; Sigler, A.; Rhee, J.S.; Brose, N.; Enk, C.; Reim, K.; Rosenmund, C. Total arrest of spontaneous and evoked synaptic transmission but normal synaptogenesis in the absence of Munc13-mediated vesicle priming. Proc. Natl. Acad. Sci. USA, 2002, 99, 9037-9042.
141. Augustin, I.; Rosenmund, C.; Sudhof, T.C.; Brose, N. Munc13-1 is essential for fusion competence of glutamatergic synaptic vesicles. Nature, 1999, 400, 457-461.
142. Aravamudan, B.; Fergestad, T.; Davis, W.S.; Rodesch, C.K.; Broadie, K. Drosophila UNC-13 is essential for synaptic transmission. Nat. Neurosci., 1999, 2, 965-971.
143. Richmond, J.E.; Davis, W.S.; Jorgensen, E.M. UNC-13 is required for synaptic vesicle fusion in C. elegans. Nat. Neurosci., 1999, 2, 959-964.
144. Richmond, J.E.; Weimer, R.M.; Jorgensen, E.M. An open form of syntaxin bypasses the requirement for UNC-13 in vesicle priming. Nature, 2001, 412, 338-341.
145. Dulubova, I.; Sugita, S.; Hill, S.; Hosaka, M.; Fernandez, I.; Sudhof, T.C.; Rizo, J. A conformational switch in syntaxin during exocytosis: role of munc18. EMBO J., 1999, 18, 4372-4382.
146. Hand, C.K.; Khoris, J.; Salachas, F.; Gros-Louis, F.; Lopes, A.A.; Mayeux-Portas, V.; Brown, R.H., Jr.; Meininger, V.; Camu, W.; Rouleau, G.A. A novel locus for familial amyotrophic lateral sclerosis, on chromosome 18q. Am. J. Hum. Genet., 2002, 70, 251-256.
147. Sapp, P.C.; Hosler, B.A.; McKenna-Yasek, D.; Chin, W.; Gann, A.; Genise, H.; Gorenstein, J.; Huang, M.; Sailer, W.; Scheffler, M.; Valesky, M.; Haines, J.L.; Pericak-Vance, M.; Siddique, T.; Horvitz, H.R.; Brown, R.H., Jr. Identification of two novel loci for dominantly inherited familial amyotrophic lateral sclerosis. Am. J. Hum. Genet., 2003, 73, 397-403.
148. Nishimura, A.L.; Mitne-Neto, M.; Silva, H.C.; Richieri-Costa, A.; Middleton, S.; Cascio, D.; Kok, F.; Oliveira, J.R.; Gillingwater, T.; Webb, J.; Skehel, P.; Zatz, M. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am. J. Hum. Genet., 2004, 75, 822-831.
149. Chow, C.Y.; Landers, J.E.; Bergren, S.K.; Sapp, P.C.; Grant, A.E.; Jones, J.M.; Everett, L.; Lenk, G.M.; McKenna-Yasek, D.M.; Weisman, L.S.; Figlewicz, D.; Brown, R.H.; Meisler, M.H. Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. Am. J. Hum. Genet., 2009, 84, 85-88.
150. Puls, I.; Jonnakuty, C.; LaMonte, B.; Holzbaur, E.; Tokito, M.; Mann, E.; Floeter, M.; Bidus, K.; Drayna, D.; Oh, S.; Brown, R.; Ludlow, C.; Fischbeck, K. Mutant dynactin in motor neuron disease. Nat. Genet., 2003, 33, 455-456.
151. Munch, C.; Sedlmeier, R.; Meyer, T.; Homberg, V.; Sperfeld, A.D.; Kurt, A.; Prudlo, J.; Peraus, G.; Hanemann, C.O.; Stumm, G.; Ludolph, A.C. Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology, 2004, 63, 724-726.
152. Figlewicz, D.A.; Krizus, A.; Martinoli, M.G.; Meininger, V.; Dib, M.; Rouleau, G.A.; Julien, J.P. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum. Mol. Genet., 1994, 3, 1757-1761.
153. Al-Chalabi, A.; Andersen, P.M.; Nilsson, P.; Chioza, B.; Andersson, J.L.; Russ, C.; Shaw, C.E.; Powell, J.F.; Leigh, P.N. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum. Mol. Genet., 1999, 8, 157-164.
154. Hosler, B.A.; Siddique, T.; Sapp, P.C.; Sailor, W.; Huang, M.C.; Hossain, A.; Daube, J.R.; Nance, M.; Fan, C.; Kaplan, J.; Hung, W.Y.; McKenna-Yasek, D.; Haines, J.L.; Pericak-Vance, M.A.; Horvitz, H.R.; Brown, R.H., Jr. Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA, 2000, 284, 1664-1669.
155. Yang, Y.; Hentati, A.; Deng, H.X.; Dabbagh, O.; Sasaki, T.; Hirano, M.; Hung, W.Y.; Ouahchi, K.; Yan, J.; Azim, A.C.; Cole, N.; Gascon, G.; Yagmour, A.; Ben-Hamida, M.; Pericak-Vance, M.; Hentati, F.; Siddique, T. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat. Genet., 2001, 29, 160-165.
156. Hadano, S.; Hand, C.K.; Osuga, H.; Yanagisawa, Y.; Otomo, A.; Devon, R.S.; Miyamoto, N.; Showguchi-Miyata, J.; Okada, Y.; Singaraja, R.; Figlewicz, D.A.; Kwiatkowski, T.; Hosler, B.A.; Sagie, T.; Skaug, J.; Nasir, J.; Brown, R.H., Jr.; Scherer, S.W.; Rouleau, G.A.; Hayden, M.R.; Ikeda, J.E. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat. Genet., 2001, 29, 166-173.
157. Chen, Y.Z.; Bennett, C.L.; Huynh, H.M.; Blair, I.P.; Puls, I.; Irobi, J.; Dierick, I.; Abel, A.; Kennerson, M.L.; Rabin, B.A.; Nicholson, G.A.; Auer-Grumbach, M.; Wagner, K.; De Jonghe, P.; Griffin, J.W.; Fischbeck, K.H.; Timmerman, V.; Cornblath, D.R.; Chance, P.F. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am. J. Hum. Genet., 2004, 74, 1128-1135.
158. Hentati, A.; Ouahchi, K.; Pericak-Vance, M.; Nijhawan, D.; Ahmad, A.; Yang, Y.; Rimmler, J.; Hung, W.-Y.; Schlotter, B.; Ahmed, A.; Ben Hamida, M.; Hentati, F.; Siddique, T. Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers. Neurogenetics, 1998, 2, 55-60.